Myovant Sciences Ltd $ 16.9 0.25 (1.5%)
Volume:
515,205
Avg Vol (1m):
990,349
Market Cap $:
1.52 Bil
Enterprise Value $:
1.63 Bil
P/E (TTM):
0.00
P/B:
0.00
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.48 | ||
| Equity-to-Asset | -1.06 | ||
| Debt-to-Equity | -1.53 | ||
| Debt-to-EBITDA | -0.86 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | -11.11 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -729.9 | ||
| Net Margin % | -761.84 | ||
| ROA % | -159.32 | ||
| ROC (Joel Greenblatt) % | -1910.27 | ||
| 3-Year EBITDA Growth Rate | -23.4 | ||
| 3-Year EPS without NRI Growth Rate | -25.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 45.31 | ||
| EV-to-EBIT | -6.74 | ||
| EV-to-EBITDA | -6.8 | ||
| EV-to-Revenue | 48.89 | ||
| Current Ratio | 2.07 | ||
| Quick Ratio | 2.07 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -14.84 |